Breast cancer

Cancer cells
#Antibody drug conjugate (ADC) #AstraZeneca #Breast cancer #Daiichi Sankyo #FDA #Oncology

FDA approved ADC improves breast cancer survival by 37%

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan-dlnk (Datroway) a Trop-2-directed antibody and topoisomerase inhibitor conjugate, as a treatment for breast cancer.  The decision was based on the results of the Phase III TROPION-Breast01 trial which showed a 37% reduction in the risk of disease progression or… Read More

#News #Regulatory

Breast cancer cell
#Breast cancer #Cancer research #Gene mutation #National Institute for Health and Care Excellence (NICE) #Regulatory

NICE approves first ESR1-mutated metastatic breast cancer drug

Final draft guidance from the UK’s National Institute for Health and Care Excellence (NICE) recommends the use of elacestrant, the first tailored treatment for locally advanced and metastatic breast cancer with mutations in the ESR1 gene. Specifically, the drug will be available on the NHS to treat post-menopausal women, and… Read More

#Cancer Research #News #Regulatory

Medical professional examining mammogram
#Breast cancer #Molecular glue degrader #Monte Rosa Therapeutics #Oncology

Selective oral CDK2 degrader shows promise in breast cancer models

According to new data, a cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader (MGD) drove deep tumour regression in preclinical models of HR-positive/HER2-negative breast cancer.  Monte Rosa Therapeutics will present the preclinical data at the 2024 San Antonio Breast Cancer Symposium, held 10-13 December in San Antonio, Texas. Read More

#Cancer Research #News

Cancer research in laboratory
#Breast cancer #Drug approvals #Drug discovery #Oncology

Early breast cancer drug Kisqali gets EU recommendation 

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorisation for Novartis’ Kisqali (ribociclib).  The positive opinion relates to the adjuvant treatment of adults with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC),… Read More

#Cancer Research #News

Breast Cancer Awareness Month
#Breast cancer #Cancer research #Cancer Research UK #Cancer therapeutics #Oncology

How close is a cure for breast cancer?

This Breast Cancer Awareness Month, Diana Spencer takes a look at the current situation and the new therapies on the horizon. Breast cancer is the most common cancer globally, with around 2.3 million new cases every year, according to data from the World Health Organization (WHO). It represents one in… Read More

#Cancer Research #Editor's Choice #Exclusive Content

Cancer cell
#AstraZeneca #Breast cancer #EU #Gene mutation #MHRA #Oncology

Capivasertib approved for advanced breast cancer in the UK

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AstraZeneca’s capivasertib (Truqap) for patients with advanced hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer. It is approved in cancers that have one or more abnormal PIK3CA, AKT1, or PTEN gene, and does… Read More

#News #Regulatory

#Breast cancer #Cancer research #DNA mutations #Epigenetics #Gene therapy #Oncology

New podcast shining a spotlight on cancer research developments

This is the latest episode of the free DDW narrated podcast, titled “How to utilise clinical trials in drug discovery” which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: The ‘dark matter’ behind cancer and Could this ‘Goldilocks’… Read More

#Cancer Research #News

Medical professional examining mammogram
#Breast cancer #Korea University #Oncology #Treatment resistance

Inhibitor overcomes drug resistance in HER2-positive breast cancer

Korean scientists have found that HVH-2930, an innovative HSP90 inhibitor, demonstrates promising efficacy in inducing cancer cell apoptosis and overcoming treatment resistance in HER2-positive breast cancer. Unlike previous HSP90 inhibitors, the compound circumvents limitations by bypassing heat shock response (HSR) induction. Professor Jae Hong… Read More

#Cancer Research #Editor's Choice #News

Cancer cells
#Breast cancer #Cancer research #CAR-T #Cell therapy #Oncology

eBook: Breakthroughs in oncology research and drug discovery

While the age-adjusted overall cancer death rate in the US fell by 33% between 1991 and 2020, cancer remains a significant threat to human health, with more than two million new cases expected to be diagnosed in 2024 and uneven progress across different cancer types1. These… Read More

#News

#Breast cancer #Clinical trials #Covid-19 #DDW Highlights podcast #FDA #lcohol Use Disorder #Mergers and acquisitions #Psychedelics

New DDW Highlights podcast: 2 April 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In another busy week for drug discovery and development, we have seen the FDA… Read More

#News

#Alcohol Use Disorder #Breast cancer #Clinical trials #Covid-19 #FDA #Mergers and acquisitions #Psychedelics

This week in drug discovery (25-29 March) 

News round-up for 25-29 March by DDW Digital Content Editor Diana Spencer. In another busy week for drug discovery and development, we have seen the FDA approval of a monoclonal antibody for emergency use in Covid-19, the launch of trials into innovative new treatments for urea cycle disorders… Read More

#News

Cancer cells
#Breast cancer #Drug targets #Epigenetics #Oncology #The Institute of Cancer Research

Research uncovers how to target dormant breast cancer cells

Scientists have discovered how breast cancer cells can ‘hibernate’ to avoid treatment and ‘wake up’ years later – causing a relapse that is more difficult to treat. Their research, published in the journal Cancer Discovery, reveals the role of epigenetics in controlling how cancer cells can… Read More

#Cancer Research #News

#Arvinas #Breast cancer #FDA #Oncology #Pfizer #PROTAC #Protein degradation

PROTAC degrader for ER+/HER2- breast cancer gets fast-tracked

Arvinas and Pfizer’s vepdegestrant (ARV-471) has received Fast Track Designation from the US Food and Drug Administration (FDA) for the treatment of patients with ER+/HER2- metastatic breast cancer. Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC) protein degrader designed to target and degrade the estrogen receptor (ER) protein. Fast Track… Read More

#Cancer Research #News #Regulatory

Checking a baby's glucose levels
#Breast cancer #Drug repurposing #Endocrinology #Paediatrics #Sidra Medicine

Breast cancer drug repurposed for congenital hyperinsulinism

In a world first, Sidra Medicine, a member of Qatar Foundation, has pioneered a new treatment protocol for a young infant with congenital hyperinsulinism. The findings were published in the New England Journal of Medicine. As the patient wasn’t responding to conventional medical therapies, the Sidra… Read More

#News

#Breast cancer #Cancer research #Colorectal cancer #Leukaemia #Lung cancer #Oncology #Pancreatic cancer

New DDW Highlights podcast: 29 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In the same week that it was revealed that breast cancer was the most… Read More

#News

#Breast cancer #Cancer research #Colorectal cancer #Leukaemia #Lung cancer #Oncology #Pancreatic cancer

This week in drug discovery (22-26 January) 

News round-up for 22-26 January by DDW Digital Content Editor Diana Spencer. In the same week that it was revealed that breast cancer was the most studied disease area in 2023 for the third year running, there were a number of promising developments in the treatment of colorectal,… Read More

#News